Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This phase Ib trial studies the side effects and best dose of telaglenastat hydrochloride
when given together with osimertinib in treating patients with stage IV non-small cell lung
cancer and a mutation in the EGFR gene. Telaglenastat hydrochloride and osimertinib may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth.